An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

Stadler W.M.Vaughn D.J.Sonpavde G.Vogelzang N.J.Tagawa S.T.Petrylak D.P.Rosen P.CHIA-CHI LINMahoney J.Modi S.Lee P.Ernstoff M.S.Su W.-C.Spira A.Pilz K.Vinisko R.Schloss C.Fritsch H.Zhao C.Carducci M.A.2022-09-152022-09-1520140008-543Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84899409111&doi=10.1002%2fcncr.28519&partnerID=40&md5=ea3fef1a1a36ce99bf4722c8849f221dhttps://scholars.lib.ntu.edu.tw/handle/123456789/620309[SDGs]SDG3An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancerjournal article10.1002/cncr.28519243390282-s2.0-84899409111